Waters Introduces Unrivaled Sensitivity and Speed to Benchtop HRMS with Xevo MRT P10 MS, Accelerating Multiomics Research
StockNews.AI · 2 hours
AI Summary
Waters introduced the Xevo MRT P10 MS, delivering up to 20x MS/MS sensitivity and twice the acquisition speed. When paired with the DESI XS source, imaging reaches 200 Hz and six-fold throughput, enhancing multiomics studies. Global availability is expected in summer 2026, with ASMS 2026 highlighting early demand.
Sentiment Rationale
Direct product upgrade with clear performance gains could drive near-term lab orders and upgrade cycles; hardware catalysts historically lift names like Waters when the new platform materially enhances throughput and sensitivity, though adoption can be gradual.
Trading Thesis
Bullish on WAT in the near term as Xevo MRT P10 MS launch could lift instrument demand in 2H 2026.
Market-Moving
- Xevo MRT P10 MS claims up to 20x MS/MS sensitivity versus prior model.
- DESI XS imaging up to 200 Hz, with six-fold throughput increase.
- Global launch expected summer 2026; ASMS 2026 to spark initial interest.
- Potential near-term uplift for Waters' instrument business and service mix.
Key Facts
- Waters unveils Xevo MRT P10 MS with up to 20x MS/MS sensitivity.
- Acquisition speeds double; DESI XS enables 200 Hz imaging.
- Identifies up to 40% more lipids vs leading benchtop HRMS.
- Global availability starts summer 2026; showcased at ASMS 2026.
- P10 MS targets multiomics, proteomics, lipidomics and biopharma analyses.
Companies Mentioned
- Waters Corporation (WAT): Announces Xevo MRT P10 MS; potential near-term uplift in instrument bookings and service revenue.
Industry News
Industry News: product launch highlighting Waters' upgraded benchtop HRMS capabilities and its impact on multiomics workflows and biopharma analytics.